The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs
Gary M Oderda, Grant D Lawless, Grace C Wright, Samuel R Nussbaum, Renwyck Elder, Kibum Kim, Diana I Brixner, Gary M Oderda, Grant D Lawless, Grace C Wright, Samuel R Nussbaum, Renwyck Elder, Kibum Kim, Diana I Brixner
Abstract
Rheumatoid arthritis (RA) management requires monitoring of disease activity to determine course of treatment. Global assessments are used in clinical practice to determine RA disease activity. Monitoring disease activity via biomarkers may also help providers optimize biologic and nonbiologic drug use while decreasing overall drug spend by delaying use of expensive biologic therapies. By testing multiple biologic domains at the same time, a multibiomarker disease activity test may have utility in RA patient management, through improved intra- and inter-rater reliability. This report provides a comprehensive review of studies of objective measures, single biomarkers and multibiomarker disease activity tests as disease activity measures to decrease uncertainty in treatment decisions, and of biomarkers' potential impact on economic and clinical outcomes of treatment choices.
Keywords: MBDA; biomarkers; outcomes; personalized medicine; rheumatoid arthritis; targeted therapy.
Source: PubMed